Logo

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

Share this

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

Shots:

  • The P-III study evaluate the efficacy, safety & immunogenicity of BCD-021 (q3w for 6 cycles) vs Avastin + paclitaxel & carboplatin in 357 patients with stage IIIB or IV nonsq. NSCLC across Russia, Belarus, Ukraine & India
  • The results showed an equivalent efficacy when assessed as risk difference & risk ratio; ORR (34.6% & 33.8%) while 341 patients had 1 CT scan after initiation of treatment; patients with SD, CR or PR @18wks. were offered BCD-021 until disease progression, death, or unacceptable toxicity
  • Additionally, baseline characteristics were balanced b/w BCD-021 and reference bevacizumab. The biosimilars will broaden the access of various populations to bevacizumab therapy

Ref: Biocad  | Image: CPhl Online

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions